Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific (BSX) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.39 per share a year ago.

Boston Scientific (BSX) Q1 Earnings and Revenues Surpass Estimates

Boston Scientific reported better-than-expected first-quarter growth on Tuesday, pushing BSX stock closer to a profit-taking zone. The post Boston Scientific Approaches A Profit-Taking Zone On First-Quarter Beat appeared first on Investor's Business Daily.

Boston Scientific Approaches A Profit-Taking Zone On First-Quarter Beat

Boston Scientific (NYSE:BSX) has reported first-quarter revenue and earnings that beat its own guidance as well as Wall Street's expectations due to strong growth at its MedSurg and Cardiovascular units, sending its shares higher in pre-market trading.  The Marlborough, Massachusetts-based medical products company said net sales increased 12% to $3.39 billion on a reported basis for the three months to March 31, 2023, above its guidance range of 3% to 5%.

Boston Scientific reports 1Q sales and earnings above guidance

Shares of Boston Scientific Corp. BSX jumped 2.8% into record territory in premarket trading Wednesday, after the medical technology company reported first-quarter results that beat expectations and raised its full-year outlook, citing a “robust pipeline” in 2023 and beyond. Net income jumped to $300 million, or 21 cents a share, from $97 million, or 7 cents a share, in the year-ago period.

Boston Scientific stock jumps into record territory after earnings beat, raised outlook

MARLBOROUGH, Mass. , April 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis and 14.0 percent on an organic2 basis, all compared to the prior year period.

Boston Scientific Announces Results for First Quarter 2023

A rise in elective surgeries performed and market share gains for some of its products will likely aid the company's top-line growth.

New Product Launches To Aid Boston Scientific's Q1

Boston Scientific is considering a takeover of Shockwave Medical, according to a report Friday that sent SWAV stock soaring. The post Shockwave Rockets As Boston Scientific Reportedly Mulls A Takeover appeared first on Investor's Business Daily.

Shockwave Rockets As Boston Scientific Reportedly Mulls A Takeover

DexCom

Stryker

The healthcare sector has been looking fit in the past month, with medical products makers Stryker Corp. (NYSE: SYK) and Boston Scientific Corp. (NYSE: BSX) rallying to all-time highs, while sector peer DexCom Inc. (NASDAQ: DXCM) is forming a constructive base.

Healthcare Innovation Drives Medical Device Makers To New Highs

Edwards Lifesciences

Stryker, Edwards Lifesciences and Boston Scientific shares outperform the broader healthcare sector as procedure volumes rebound and costs stabilize.

Medical-Device Makers Gain Amid Return to Normalcy

Boston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and the long-term growth prospects of the WATCHMAN device.

Boston Scientific (BSX) Hits 52-Week High: What's Driving It?

MARLBOROUGH, Mass. , April 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26, 2023 at 8:00 a.m.

Boston Scientific Announces Conference Call Discussing First Quarter 2023 Results

“XLV” – the Health Care Select Sector SPDR Fund has been a disappointment for investors since the start of the year but a portfolio manager says it'll likely be a different story moving forward.

Pro reveals healthcare stocks that are worth buying right now

Varex Imaging

VREX vs. BSX: Which Stock Is the Better Value Option?

VREX or BSX: Which Is the Better Value Stock Right Now?

Boston Scientific stock (NYSE: BSX) has seen a fall of 3% in a month, compared with -5% returns for the broader S&P500 index.

Will Boston Scientific Stock See Higher Levels?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Boston Scientific Corporation (NYSE: BSX).

BOSTON SCIENTIFIC INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX

Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.

Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay

Boston Scientific came up short on margins in the fourth quarter, but reassuring guidance on revenue and improved margins in FY'23 seems to have smoothed that over. Boston Scientific has an above-average forward growth profile among larger med-techs, with multiple drivers including Watchman, ablation, structural heart, urology, and peripheral interventions.

Boston Scientific Stands Out With Strong, Diversified Growth Profile

MARLBOROUGH, Mass. , Feb. 13, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Wednesday, March 1, 2023.

Boston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference

NEW ORLEANS , Feb. 3, 2023 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

BOSTON SCIENTIFIC INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX

New technology designed to help inform real-time clinical decisions during kidney stone procedures MARLBOROUGH, Mass. , Feb. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System, the first ureteroscope system with the ability to monitor intrarenal pressure in real-time during ureteroscopy procedures.

Boston Scientific Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System

Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in the fourth quarter of 2022.

Boston Scientific (BSX) Q4 Earnings Miss, Operating Margin Up

Boston Scientific Corporation (NYSE:BSX ) Q4 2022 Results Conference Call February 1, 2023 8:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Mike Mahoney - Chairman & Chief Executive Officer Dan Brennan - Executive Vice President & Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Rick Wise - Stifel Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Josh Jennings - Cowen Operator Good morning, and welcome to the Boston Scientific Fourth Quarter 2022 Earnings Call. All participants will be in listen only mode [Operator Instructions] Please note, this event is being recorded.

Boston Scientific Corporation (BSX) Q4 2022 Earnings Call Transcript

Thermo Fisher Scientific

Thermo Fisher easily beat quarterly projections, while Boston Scientific was in line. TMO stock popped Wednesday while BSX stock also rose.

Thermo Fisher Pops On Its Bullish Outlook As Boston Scientific Gains On Its In-Line Report

Boston Scientific (BSX) delivered earnings and revenue surprises of -4.26% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Lags Q4 Earnings Estimates

Boston Scientific Corp. stock BSX, +0.96% slid 5% in premarket trade Wednesday, after the medical device maker missed profit estimates for the fourth quarter. The company had net income of $126 million, or 9 cents a share, up from $80 million, or 6 cents a share, in the year-earlier period.

News for Boston Scientific Stock (BSX)